genetics. However, prognosis of the disease needs to be established in such patient groups. The commercially available dual-color dual-fusion FISH probes have revolutionized cancer cytogenetics. Using these probes, it has become easy to analyze the genetic abnormalities on metaphases even in interphase cells. The advantage of D-FISH is that, it is helpful in identifi cation of variant translocations, deletions and gene fusions. In chronic myeloid leukemia (CML), 9q and 22q deletions have been reported in a good number of patients in the literature, and such patients behave as classical CML. In some CML patient groups, there may be a chance of deletions of ABL1 gene fl anking regions, and these regions need to be mapped using locus-specific probes and the microRNA expression studies, which is an emerging tool in cancer genetics and can be used to assess the patients.
The reciprocal translocation represents the most chromosome aberrations in hematological malignancies.
These translocations usually affect oncogenes that have been identifi ed in almost all of the cancer conditions that lead to the genesis of abnormal fusion genes, resulting in the mutation or overexpression of components of the fused genes. [3] The CML, which is associated with Philadelphia chromosome resulting from t(9;22)(q34.1; genes. However, there is a need of more work at the molecular level to understand the disease development and progression. [5] The As modern tools of cytogenetics and molecular biology are increasingly applied to various hematological malignancies, inherent heterogeneity leading to biological differences in the ultimate outcome of these patients on various therapies are coming to the fore. Moreover, depending on this molecular pathology, various molecular targeted therapies are being increasingly applied in these conditions with salutary results. It is hoped that many more such studies will complete our understanding of the heterogeneity of various hematological malignancies.
